In the evolving landscape of regenerative medicine, AURAGENS has distinguished itself through a combination of scientific rigor, ethical practice, and patient-centered care. Over the past year, the company has expanded its capabilities, demonstrating meaningful improvements in the efficacy, safety, traceability, and transparency of its therapies; And in doing so became our first two-time selection as Stem Cell Treatment Center the Year 2026. AURAGENS, has created and entire regenerative medical platform well-beyond what we have seen with standard treatment centers. From tissue sourcing to cell expansion, to clinical administration, to publication of results and peer reviewed papers – AURAGENS has created an entire ecosystem under their control to ensure the quality of its biologics and provide the expected results to its patients. Under the leadership of CEO Dr. Daniel S. Briggs, AURAGENS has consistently sought to raise the bar, pushing higher standards in an industry often criticized for hype, inconsistency, and a lack of oversight. Reflecting on these achievements, Dr. Briggs notes, “We have seen significant growth over the last year, specifically in the efficacy, safety, and transparency of how our biologics are created and the results we are monitoring.”

Every year, promising life sciences innovations fail to reach patients because the path to commercialization breaks down well before market entry. Unfortunately, this is a systemic and pervasive challenge across the sector. Emerging healthcare companies operate in a highly specialized landscape yet rely on generalist advisors with strong financial expertise but no scientific, clinical, and market insight. This disconnect often leaves promising but complex technologies poorly positioned, making it difficult to secure the right partnerships, funding, and commercialization strategies needed to bring innovation to the patients who need them. Outcome Capital was built to change that, recognizing that the knowledge-, risk , and capital intensive life science industry is fundamentally not suited to traditional advisory approaches. The firm acts as the missing link between breakthrough technologies and the patients who stand to benefit from them, helping emerging and growth-stage life sciences companies navigate from innovation to commercialization. Founded by life sciences veterans and built around a multidisciplinary team of scientists, clinicians, industry executives, and financial professionals, the firm operates at the intersection of science, strategy, and transaction execution. It helps emerging and growth-stage companies align innovation with market demand and clear commercialization pathways. “We see ourselves as the missing link between promising technologies and the patients,” says Oded Ben-Joseph, PhD, MBA, co-founder and managing partner..

The longevity sector continues to expand rapidly, yet many approaches remain focused on treating individual diseases or promoting isolated ingredients without addressing the underlying drivers of aging. This fragmented approach often limits the ability to influence long-term health outcomes in a measurable way. NOVOS Labs approaches this challenge by targeting aging itself as the primary driver of chronic disease. Its work is built on a systems-level understanding of aging biology, addressing multiple biological pathways simultaneously rather than focusing on single outcomes. “At NOVOS Labs, our philosophy begins with a simple premise: aging itself is the primary driver of most chronic diseases,” says Hannah Gates, director of business development. Moving Beyond Single-Ingredient Approaches A key issue in the longevity supplement space is the prevalence of products built around individual compounds with limited scientific validation. Aging is a complex process involving interconnected systems, yet many solutions fail to reflect this complexity..